RxDoctor Payments Data

Katherine Fu, MD

Neurology · Los Angeles, CANPI 1043743362

Payments from drug & device makers

$3,860in general payments, 2019–2025

Across 70 payments — averaging $55.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Boston Scientific$800
  • Neurocrine Biosciences, Inc.$477
  • Abbott$389
  • Amneal Pharmaceuticals LLC$206
  • Acadia Pharmaceuticals Inc$197
  • plus $379 from 6 others
$290in research payments, 2019–2025

Across 1 payment — averaging $290.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$290

What the payments were for

  • Travel & lodging$81221%
  • Food & beverage$2,58667%
  • Education$46312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,860 in reported general payments places this provider in the 60th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$104,691
Medicare patients
112
Services billed
7,531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate22$126,244
RytaryCarbidopa/Levodopa35$49,974
BelsomraSuvorexant11$5,208
Entacapone15$5,124
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone18$5,085
Carbidopa15$4,901
Carbidopa-LevodopaCarbidopa/Levodopa103$4,116
Rasagiline Mesylate13$2,630
Carbidopa-Levodopa ErCarbidopa/Levodopa42$1,906
Propranolol Hcl ErPropranolol Hcl16$647
Mirtazapine14$478
Clonazepam33$392
Trazodone Hcl21$339
Buspirone Hcl17$311
Sertraline Hcl21$273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$197$126,24422 claims
Amneal Pharmaceuticals LLCRytary$206$49,97435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,996 neurology providers in California.

Other neurology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →